G.D. Kotzalidis, R. Brugnoli, V. Orlandi, M. Donnini, A. Parmegiani, P. Pancheri - Vol. 7, Settembre 2001, num.3
Testo Immagini Bibliografia Summary Riassunto Indice
Neurobiologia degli Attacchi di Panico
Neurobiology of panic attacks
1 American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 3rd edition (DSM-III). Washington DC: American Psychiatric Association Press 1980.
2 Klein DF. Anxiety reconceptualized. In: Klein DF, Rabkin J, eds. Anxiety: New Research and Changing Concepts. New York: Raven Press 1981.
3 Shear MK. Panic disorder with and without agoraphobia. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry. Philadelphia Pa: W.B. Saunders 1997;2:1020-36.
4 Norman TR, Judd FK, Burrows GD, McIntyre IM. Platelet serotonin uptake in panic disorder patients: a replication study. Psychiatry Res 1989;30:63-8.
5 Norman TR, Judd FK, Staikos V, Burrows GD, McIntyre IM. High-affinity platelet [3H]LSD binding is decreased in panic disorder. J Affect Disord 1990;19:119-23.
6 Gurguis GN, Antai-Otong D, Vo SP, Blakeley JE, Orsulak PJ, Petty F, et al. Adrenergic receptor function in panic disorder. I. Platelet a2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology 1999;20:162-76.
7 Sullivan GM, Coplan JD. Anxiety Disorders: Biochemical Aspects. In: Sadock BJ, Sadock VA, eds. Kaplan-Sadock’s Comprehensive Textbook of Psychiatry/VII 7th edition. Philadelphia (Pa)-Baltimore (Md): Lippincott Williams & Wilkins 2000.
8 Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
9 Fontaine R, Breton G, Dery R, Fontaine S, Elie R. Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry 1990;27:304-10.
10 Ontiveros A, Fontaine R, Breton G, Elie R, Fontaine S, Dery R. Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. J Neuropsychiatry Clin Neurosci 1989;1:404-8.
11 Dantendorfer K, Prayer D, Kramer J, Amering M, Baischer W, Berger P, et al. High frequency of EEG and MRI brain abnormalities in panic disorder. Psychiatry Res 1996;68:41-53.
12 Vythilingam M, Anderson ER, Goddard A, Woods SW, Staib LH, Charney DS, et al. Temporal lobe volume in panic disorder – a quantitative magnetic resonance imaging study. Psychiatry Res 2000;99:75-82.
13 Lucey JV, Costa DC, Busatto G, Pilowsky LS, Marks IM, Ell PJ, et al. Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography. Psychiatry Res 1997;74:25-33.
14 Lucey JV, Costa DC, Adshead G, Deahl M, Busatto G, Gacinovic S, et al. Brain blood flow in anxiety disorders. OCD, panic disorder with agoraphobia, and post-traumatic stress disorder on 99mTcHMPAO single photon emission tomography (SPET). Br J Psychiatry 1997;171:346-50.
15 Stewart RS, Devous MD Sr, Rush AJ, Lane L, Bonte FJ. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry 1988;145:442-9.
16 Potokar J, Lawson C, Wilson S, Nutt D. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry 1999;46:1709-11 (comment on: Biol Psychiatry 1999;45:321-6).
17 Kaschka W, Feistel H, Ebert D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 1995;29:427-34.
18 Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by Iomazenil SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci 1994;244:49-51.
19 Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000;47:96-106.
20 Vasar E, Harro J, Pôld A, Lang A. CCK receptors and anxiety in rats. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple Cholecystokinin Receptors in the CNS. Oxford: Oxford University Press 1992:143-8.
21 Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P, et al. The application of positron emission tomography to the study of panic disorder. Am J Psychiatry 1986;143:469-77.
22 Reiman EM. PET, panic disorder, and normal anticipatory anxiety. In: Ballenger JC, ed. Neurobiology of Panic Disorder. New York: Wiley-Liss 1990:245-70.
23 De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry 1993;33:505-12.
24 Reiman EM. The study of panic disorder using positron emission tomography. Psychiatr Dev 1987;5:63-78.
25 Fischer H, Andersson JL, Furmark T, Fredrikson M. Brain correlates of an unexpected panic attack: a human positron emission tomographic study. Neurosci Lett 1998;251:137-40.
26 Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-20.
27 Meyer MA, Zimmerman AW, Miller CA. Temporal lobe epilepsy presenting as panic attacks: detection of interictal hypometabolism with positron emission tomography. J Neuroimaging 2000;10:120-2.
28 Jensen CF, Peskind ER, Keller TW, McFall ME, Raskind MA. Comparison of sodium lactate-induced panic symptoms between panic disorder and posttraumatic stress disorder. Depress Anxiety 1998;7:122-5.
29 Facchinetti F, Romano G, Fava M, Genazzani AR. Lactate infusion induces panic attacks in patients with premenstrual syndrome. Psychosom Med 1992;54:288-96 (comment in: Psychosom Med 1993;55:86-7).
30 McGrath PJ, Stewart JW, Liebowitz MR, Markowitz JM, Quitkin FM, Klein DF, et al. Lactate provocation of panic attacks in depressed outpatients. Psychiatry Res 1988;25:41-7.
31 Cowley DS, Dager SR, Dunner DL. Lactate-induced panic in primary affective disorder. Am J Psychiatry 1986;143:646-8.
32 Balon R, Jordan M, Pohl R, Yeragani VK. Family history of anxiety disorders in control subjects with lactate-induced panic attacks. Am J Psychiatry 1989;146:1304-6.
33 Yeragani VK, Pohl R, Balon R, Weinberg P, Berchou R, Rainey JM. Preinfusion anxiety predicts lactate-induced panic attacks in normal controls. Psychosom Med 1987;49:383-9.
34 Rosse RB, Deutsch LH, Deutsch SI. 7.7 Medical Assessment and Laboratory Testing in Psychiatry. In: Sadock BJ, Sadock VA, eds. Kaplan-Sadock’s Comprehensive Textbook of Psychiatry/VII 7th edition. Philadelphia (Pa)-Baltimore (Md): Lippincott Williams & Wilkins 2000.
35 Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF. Measurement of lactate-induced panic and anxiety. Psychiatry Res 1987;20:97-105.
36 Coplan JD, Goetz R, Klein DF, Papp LA, Fyer AJ, Liebowitz MR, et al. Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 1998;55:130-6.
37 George DT, Lindquist T, Ragan PW, Alim T, Eckardt MJ, Linnoila M. Effect of alcoholism on the incidence of lactate-induced panic attacks. Biol Psychiatry 1997;42:992-9.
38 Dager SR, Cowley DS, Dunner DL. Biological markers in panic states: lactate-induced panic and mitral valve prolapse. Biol Psychiatry 1987;22:339-59.
39 Moigné E, Pichène C, Hennequin L, Hoffman M, Lambert H, Larcan A. Absence de prolapsus mitral au cours d’attaques de panique provoquées par lactate de sodium. Presse Méd 1993;22:850-4.
40 Levin AP, Doran AR, Liebowitz MR, Fyer AJ, Gorman JM, Klein DF, Paul SM. Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 1987;21:23-32.
41 Seier FE, Kellner M, Yassouridis A, Heese R, Strian F, Wiedemann K. Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol 1997;272:H2630-H2638.
42 Kellner M, Herzog L, Yassouridis A, Holsboer F, Wiedemann K. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry 1995;152:1365-7.
43 Cowley DS, Adams JB, Pyke RE, Cook J, Zaccharias P, Wingerson D, et al. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996;40:550-2.
44 van Megen HJ, Westenberg HG, den Boer JA. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients. Biol Psychiatry 1996;40:804-6.
45 Balon R, Pohl R, Yeragani VK, Rainey JM Jr, Berchou R. Follow-up study of control subjects with lactate- and isoproterenol-induced panic attacks. Am J Psychiatry 1988;145:238-41.
46 Gorman JM, Battista D, Goetz RR, Dillon DJ, Liebowitz MR, Fyer AJ, et al. A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Arch Gen Psychiatry 1989;46:145-50 (erratum appears in Arch Gen Psychiatry 1991;48:772).
47 Hibbert G, Pilsbury D. Hyperventilation: is it a cause of panic attacks? Br J Psychiatry 1989;155:805-9.
48 Spinhoven P, Onstein EJ, Sterk PJ. Hyperventilatie: geen oorzaak van paniekaanvallen. Ned Tijdschr Geneeskd 1993;137:2315-8.
49 Gorman JM, Papp LA, Coplan JD, Martinez JM, Lennon S, Goetz RR, et al. Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder. Am J Psychiatry 1994;151:547-53.
50 van Zijderveld GA, Veltman DJ, van Dyck R, van Doornen LJ. Epinephrine-induced panic attacks and hyperventilation. J Psychiatr Res 1999;33:73-8.
51 Maddock RJ, Mateo-Bermudez J. Elevated serum lactate following hyperventilation during glucose infusion in panic disorder. Biol Psychiatry 1990;27:411-8.
52 Maddock RJ, Carter CS, Gietzen DW. Elevated serum lactate associated with panic attacks induced by hyperventilation. Psychiatry Res 1991;38:301-11.
53 Dager SR, Strauss WL, Marro KI, Richards TL, Metzger GD, Artru AA. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 1995;152:666-72.
54 Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, et al. Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984;141:857-61.
55 George DT, Nutt DJ, Walker WV, Porges SW, Adinoff B, Linnoila M. Lactate and hyperventilation substantially attenuate vagal tone in normal volunteers. A possible mechanism of panic provocation? Arch Gen Psychiatry 1989;46:153-6.
56 Holt PE, Andrews G. Hyperventilation and anxiety in panic disorder, social phobia, GAD and normal controls. Behav Res Ther 1989;27:453-60.
57 Papp LA, Klein DF, Gorman JM. Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry 1993;150:1149-57.
58 Salkovskis PM, Clark DM. Affective responses to hyperventilation: a test of the cognitive model of panic. Behav Res Ther 1990;28:51-61.
59 Lee YJ, Curtis GC, Weg JG, Abelson JL, Modell JG, Campbell KM. Panic attacks induced by doxapram. Biol Psychiatry 1993;33:295-7.
60 Abelson JL, Nesse RM, Weg JG, Curtis GC. Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Psychosom Med 1996;58:302-13.
61 Abelson JL, Weg JG, Nesse RM, Curtis GC. Neuroendocrine responses to laboratory panic: cognitive intervention in the doxapram model. Psychoneuroendocrinology 1996;21:375-90.
62 Griez E, de Loof C, Pols H, Zandbergen J, Lousberg H. Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. Psychiatry Res 1990;31:193-9.
63 Sanderson WC, Wetzler S. Five percent carbon dioxide challenge: valid analogue and marker of panic disorder? Biol Psychiatry 1990;27:689-701.
64 Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, et al. Diagnostic and substance specificity of carbon-dioxide-induced panic. Am J Psychiatry 1993;150:250-7 (comments in: Am J Psychiatry 1994;151:292; Am J Psychiatry 1994;151:292-3).
65 Verburg K, Griez E, Meijer J, Pols H. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiatry 1995;152:1081-3.
66 Perna G, Gabriele A, Caldirola D, Bellodi L. Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res 1995;57:267-73.
67 Verburg K, Klaassen T, Pols H, Griez E. Comorbid depressive disorder increases vulnerability to the 35% carbon dioxide (CO2) challenge in panic disorder patients. J Affect Disord 1998;49:195-201.
68 Sinha SS, Coplan JD, Pine DS, Martinez JA, Klein DF, Gorman JM. Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 1999;86:93-8.
69 Van den Hout MA, Griez E. Panic symptoms after inhalation of carbon dioxide. Br J Psychiatry 1984;144:503-7.
70 Pineda J, Aghajanian GK. Carbon dioxide regulates the tonic activity of locus coeruleus neurons by modulating a proton- and polyamine-sensitive inward rectifier potassium current. Neuroscience 1997;77:723-43.
71 Klaassen T, Klumperbeek J, Deutz NE, van Praag HM, Griez E. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Res 1998;77:167-74.
72 Schruers K, Klaassen T, Pols H, Overbeek T, Deutz NE, Griez E. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res 2000;93:179-87.
73 Balon R, Pohl R, Yeragani VK, Rainey JM, Weinberg P. Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. Psychiatry Res 1988;23:153-60.
74 Pohl R, Yeragani VK, Balon R, Rainey JM, Lycaki H, Ortiz A, et al. Isoproterenol-induced panic attacks. Biol Psychiatry 1988;24:891-902.
75 Balon R, Yeragani VK, Pohl R. Phenomenological comparison of dextrose, lactate, and isoproterenol associated panic attacks. Psychiatry Res 1988;26:43-50.
76 Pohl R, Yeragani VK, Balon R. Effects of isoproterenol in panic disorder patients after antidepressant treatment. Biol Psychiatry 1990;28:203-14.
77 Veltman DJ, van Zijderveld GA, van Dyck R. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study. J Affect Disord 1996;39:133-40.
78 van Zijderveld GA, TenVoorde BJ, Veltman DJ, van Doornen LJ, Orlebeke JF, van Dyck R, et al. Cardiovascular, respiratory, and panic reactions to epinephrine in panic disorder patients. Biol Psychiatry 1997;41:249-51.
79 Veltman DJ, van Zijderveld GA, van Dyck R, Bakker A. Predictability, controllability, and fear of symptoms of anxiety in epinephrine-induced panic. Biol Psychiatry 1998;44:1017-26.
80 van Zijderveld GA, Veltman DJ, van Dyck R, van Doornen LJ. Epinephrine-induced panic attacks and hyperventilation. J Psychiatr Res 1999;33:73-8.
81 Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984;41:751-63.
82 Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030-6.
83 Woods SW, Koster K, Krystal JK, Smith EO, Zubal IG, Hoffer PB, et al. Yohimbine alters regional cerebral blood flow in panic disorder. Lancet 1988;2:678.
84 Gurguis GN, Uhde TW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 1990;15:217-24.
85 Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, Vittone B, et al. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 1992;6:101-18.
86 Gurguis GN, Uhde TW. Effect of yohimbine on plasma homovanillic acid in panic disorder patients and normal controls. Biol Psychiatry 1990;28:292-6.
87 Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992;86:273-82.
88 Gurguis GN, Vitton BJ, Uhde TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 1997;71:27-39.
89 Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119-33.
90 Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306 (comment in: Psychiatry Res 1990;31:209-10; Psychiatry Res 1990;31:211-3).
91 Apostolopoulos M, Judd FK, Burrows GD, Norman TR. Prolactin response to dl-fenfluramine in panic disorder. Psychoneuroendocrinology 1993;18:337-42.
92 Judd FK, Apostolopoulos M, Burrows GD, Norman TR. Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:329-37.
93 Vieira AH, Ramos RT, Gentil V. Hormonal response during a fenfluramine-associated panic attack. Braz J Med Biol Res 1997;30:887-90 (erratum in Braz J Med Biol Res 1997;30:1145).
94 Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM. Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. Psychiatry Res 2000;98:133-43.
95 Mortimore C, Anderson IM. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacology (Berl) 2000;149:251-8.
96 Solyom L. Controlling panic attacks with fenfluramine. Am J Psychiatry 1994;151:621-2.
97 Hetem LA. Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder – a case report. J Clin Psychopharmacol 1996;16:77-8.
98 Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24.
99 Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Res 1991;37:25-34.
100 Germine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 1994;54:115-33.
101 Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 1992;43:65-76.
102 Priolo E, Libri V, Lopilato R, David E, Nappi G, Nisticò G. Panic-like attack induced by microinfusion into the locus coeruleus of antagonists and inverse agonists at GABAA-receptors in rodents. Funct Neurol 1991;6:393-403.
103 Ida Y, Elsworth JD, Roth RH. Anxiogenic b-carboline FG 7142 produces activation of noradrenergic neurons in specific brain regions of rats. Pharmacol Biochem Behav 1991;39:791-3.
104 File SE, Pellow S. Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. Neurosci Lett 1985;61:115-9.
105 Lader M, Bruce M. States of anxiety and their induction by drugs. Br J Clin Pharmacol 1986;22:251-61.
106 Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:917-25 (comment in: Arch Gen Psychiatry 1992;49:329-32).
107 Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 1991;36:115-27.
108 Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 1998;155:610-2.
109 Ströhle A, Kellner M, Holsboer F, Wiedemann K. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry 1999;45:321-6 (comment in: Biol Psychiatry 1999;46:1709-11).
110 Bernik MA, Gorenstein C, Vieira Filho AH. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users. J Psychopharmacol 1998;12:146-50.
111 Bradwejn J, Koszycki D, Couetoux du Tertre A, Paradis M, Bourin M. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology (Berl) 1994;114:257-61.
112 de Belleroche J, Bandopadhyay R. Central actions of CCK: modulation of GABA release by CCK. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple Cholecystokinin Receptors in the CNS. Oxford: Oxford University Press 1992:155-8.
113 Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am J Physiol 1994;266:C1485-C1504.
114 Jorgensen AO, Shen AC, Arnold W, McPherson PS, Campbell KP. The Ca2+-release channel/ryanodine receptor is localized in junctional and corbular sarcoplasmic reticulum in cardiac muscle. J Cell Biol 1993;120:969-80.
115 Padua RA, Nagy JI, Geiger JD. Subcellular localization of ryanodine receptors in rat brain. Eur J Pharmacol 1996;298:185-9.
116 Nakanishi S, Kuwajima G, Mikoshiba K. Immunohistochemical localization of ryanodine receptors in mouse central nervous system. Neurosci Res 1992;15:130-42.
117 Wong PW, Joy RM, Albertson TE, Schantz SL, Pessah IN. Ortho-substituted 2,2’,3,5’,6-pentachlorobiphenyl (PCB 95) alters rat hippocampal ryanodine receptors and neuroplasticity in vitro: evidence for altered hippocampal function. Neurotoxicology 1997;18:443-56.
118 Nakashima Y, Nishimura S, Maeda A, Barsoumian EL, Hakamata Y, Nakai J, et al. Molecular cloning and characterization of a human brain ryanodine receptor. FEBS Lett 1997;417:157-62.
119 Islam MS, Larsson O, Nilsson T, Berggren PO. Effects of caffeine on cytoplasmic free Ca2+ concentration in pancreatic b-cells are mediated by interaction with ATP-sensitive K+ channels and L-type voltage-gated Ca2+ channels but not the ryanodine receptor. Biochem J 1995;306:679-86.
120 Feuerstein TJ, Hertting G, Jackisch R. Modulation of hippocampal serotonin (5-HT) release by endogenous adenosine. Eur J Pharmacol 1985;107:233-42.
121 Zgombick JM, Beck SG, Mahle CD, Craddock-Royal B, Maayani S. Pertussis toxin-sensitive guanine nucleotide-binding protein(S) couple adenosine A1 and 5-hydroxytryptamine1A receptors to the same effector systems in rat hippocampus: biochemical and electrophysiological studies. Mol Pharmacol 1989;35:484-94.
122 Okada M, Kawata Y, Kiryu K, Mizuno K, Wada K, Tasaki H, et al. Effects of adenosine receptor subtypes on hippocampal extracellular serotonin level and serotonin reuptake activity. J Neurochem 1997;69:2581-8.
123 Taylor DA, Stone TW. The action of adenosine on noradrenergic neuronal inhibition induced by stimulation of locus coeruleus. Brain Res 1980;183:367-76.
124 Jackisch R, Fehr R, Hertting G. Adenosine: an endogenous modulator of hippocampal noradrenaline release. Neuropharmacology 1985;24:499-507.
125 Allgaier C, Hertting G, Kugelgen OV. The adenosine receptor-mediated inhibition of noradrenaline release possibly involves an N-protein and is increased by a2-autoreceptor blockade. Br J Pharmacol 1987;90:403-12.
126 Newman F, Stein MB, Trettau JR, Coppola R, Uhde TW. Quantitative electroencephalographic effects of caffeine in panic disorder. Psychiatry Res 1992;45:105-13.
127 Deckert J, Nothen MM, Franke P, Delmo C, Fritze J, Knapp M, et al. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 1998;3:81-5.
128 Boulenger JP, Patel J, Post RM, Parma AM, Marangos PJ. Chronic caffeine consumption increases the number of brain adenosine receptors. Life Sci 1983;32:1135-42.
129 Chou DT, Cuzzone H, Hirsh KR. Assessment of blood platelets as a model for CNS response: comparative effects of caffeine on 5-HT uptake and release mechanisms in rat platelets and rat brain serotonin neurons. Life Sci 1983;33:1149-56.
130 Boulenger JP, Uhde TW, Wolff EA 3d, Post RM. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry 1984;41:1067-71.
131 Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-43.
132 Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine’s anxiogenic effects. Biol Psychiatry 1991;30:973-84.
133 Apfeldorf WJ, Shear MK. Caffeine potentiation of taste in panic-disorder patients. Biol Psychiatry 1993;33:217-9.
134 DeMet E, Stein MK, Tran C, Chicz-DeMet A, Sangdahl C, Nelson J. Caffeine taste test for panic disorder: adenosine receptor supersensitivity. Psychiatry Res 1989;30:231-42.
135 Newman F, Stein MB, Trettau JR, Coppola R, Uhde TW. Quantitative electroencephalographic effects of caffeine in panic disorder. Psychiatry Res 1992;45:105-13.
136 Lee MA, Flegel P, Greden JF, Cameron OG. Anxiogenic effects of caffeine on panic and depressed patients. Am J Psychiatry 1988;145:632-5.
137 Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000;60:1303-14.
138 van Brussel GH. Is cannabis altijd een "soft drug"? Ned Tijdschr Geneeskd 1993;137:1081-3.
139 Negrete JC. Efectos del canabismo sobre la salud. Acta Psiquiatr Psicol Am Lat 1983;29:267-76.
140 Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996;42:201-7.
141 Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981;21(Suppl. 8-9):S377-S382.
142 Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by d9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-50.
143 Sagratella S, Scotti de Carolis A, Longo VG. EEG interaction between d8-tetrahydrocannabinol and some sedative-anxiolytic drugs. Is the anxiogenic effect of Cannabis related to an action on the GABAergic system? Adv Biochem Psychopharmacol 1986;41:203-9.
144 Chesher GB, Jackson DM. Post-swim grooming in mice inhibited by dopamine receptor antagonists and by cannabinoids. Pharmacol Biochem Behav 1980;13:479-81.
145 Devane WA, Spain JW, Coscia CJ, Howlett AC. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J Neurochem 1986;46:1929-35.
146 Vaysse PJ, Gardner EL, Zukin RS. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 1987;241:534-9.
147 Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988;33:297-302.
148 Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
149 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
150 Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993;61:352-5.
151 Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993;90:7656-60.
152 Devane WA, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 1994;91:6698-701.
153 Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998;243:838-43.
154 Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999;65:573-95.
155 Lambert DM, DiPaolo FG, Sonveaux P, Kanyonyo M, Govaerts SJ, Hermans E, et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1999;1440:266-74.
156 Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1receptor. Proc Natl Acad Sci USA 2001;98:3662-5.
157 Akinshola BE, Chakrabarti A, Onaivi ES. In-vitro and in-vivo action of cannabinoids. Neurochem Res 1999;24:1233-40.
158 Navarro M, Hernandez E, Muñoz RM, del Arco I, Villanua MA, Carrera MR, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997;8:491-6.
159 Giuliani D, Ferrari F, Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 2000;41:47-53.
160 Wada JA, Wake A, Sato M, Corcoran ME. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia 1975;16:503-10.
161 Karler R, Calder LD, Turkanis SA. Changes in CNS sensitivity to cannabinoids with repeated treatment: tolerance and auxoesthesia. NIDA Res Monogr 1984;54:312-22.
162 Karler R, Calder LD, Sangdee P, Turkanis SA. Interaction between d-9-tetrahydrocannabinol and kindling by electrical andchemical stimuli in mice. Neuropharmacology 1984;23:1315-20.
163 Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978;133:1-14.
164 Carrington CD, Ellinwood EH Jr, Krishnan RR. Effects of single and repeated alcohol withdrawal on kindling. Biol Psychiatry 1984;19:525-37.
165 Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry 1988;23:507-14.
166 Becker HC, Hale RL. Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal "kindling". Alcohol Clin Exp Res 1993;17:94-8.
167 Becker HC. The alcohol withdrawal "kindling" phenomenon: clinical and experimental findings. Alcohol Clin Exp Res. 1996;20(Suppl. 8):A121-A124.
168 Matsumoto I, Burke L, Inoue Y, Wilce PA. Two models of ethanol withdrawal kindling. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001;36:53-64.
169 Araszkiewicz A, Rybakowski JK. Hoigne’s syndrome, kindling, and panic disorder. Depress Anxiety 1996-97;4:139-43.
170 Darmani NA, Pandya DK. Involvement of other neurotransmitters in behaviors induced by the cannabinoidCB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 2000;107:931-45.
171 Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001;29:729-38.
172 Auclair N, Otani S, Soubrie P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000;83:3287-93.
173 Akinshola BE, Chakrabarti A, Onaivi ES. In-vitro and in-vivo action of cannabinoids. Neurochem Res 1999;24:1233-40.
174 Sethi BB, Trivedi JK, Kumar P, Gulati A, Agarwal AK, Sethi N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol Psychiatry 1986;21:3-10.
175 Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100:558-9.
176 Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000;57:288-95.
177 Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998;70:671-6.
178 Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-50 (comment in: Science 1997;277:749; discussion 750-752;276:1967-1968).
179 McGregor IS, Arnold JC, Weber MF, Topple AN, Hunt GE. A comparison of d9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Res 1998;802:19-26.
180 Rodríguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997;276:2050-4 (comment in: Science 1997;277:749; discussion 750-752;276:1967-1968).
181 Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C a MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996;276:56-64.
182 Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000;97:6079-84.
183 Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, et al. The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001;13:373-80.
184 Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-81.
185 Onaivi ES, Chakrabarti A, Gwebu ET, Chaudhuri G. Neurobehavioral effects of d9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav Brain Res 1995;72:115-25.
186 Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993;46:967-72.
187 Gallager DW, Sanders-Bush E, Sulser F. Dissociation between behavioral effects and changes in metabolism of cerebral serotonin following 9-tetrahydrocannabinol. Psychopharmacologia 1972;26:337-45.
188 Johnson KM, Dewey WL, Harris LS. Some structural requirements for inhibition of high-affinity synaptosomal serotonin uptake by cannabinoids. Mol Pharmacol 1976;12:345-52.
189 Taylor DA, Fennessy MR. The effect of d9-tetrahydrocannabinol (d9-THC) on the turnover rate of brain serotonin of the rat. Clin Exp Pharmacol Physiol 1979;6:327-34.
190 Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000;361:19-24.
191 Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 1998;21:224-6.
192 Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995;73:907-10.
193 Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA. Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 1999;38:533-41.
194 Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 2001;132:631-40.
195 Tsou K, Mackie K, Sanudo-Pena MC, Walker JM. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999;93:969-75.
196 Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000;100:797-804.
197 Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999;19:4544-58.
198 Beinfeld MC, Connolly K. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 2001;301:69-71.
199 Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999;11:4213-25.
200 Taylor HG. Analysis of the medical use of marijuana and its societal implications. J Am Pharm Assoc (Wash) 1998;38:220-7 (comment in: J Am Pharm Assoc (Wash) 1998;38:126).
201 Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001;178:107-15.
202 Emson PC, Rehfeld JF, Rossor MN. Distribution of cholecystokinin-like peptides in the human-brain. J Neurochem 1982;38:1177-9.
203 Miller LJ, Jardine I, Weissman E, Go VL, Speicher D. Characterization of cholecystokinin from the human brain. J Neurochem 1984;43:835-40.
204 Dietl MM, Probst A, Palacios JM. On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study. Synapse 1987;1:169-83.
205 Kinze S, Schoneberg T, Meyer R, Martin H, Kaufmann R. Pharmacological characterization of CCKB receptors in human brain: no evidence for receptor heterogeneity. Neurosci Lett 1996;217:45-9.
206 Perry RH, Dockray GJ, Dimaline R, Perry EK, Blessed G, Tomlinson BE. Neuropeptides in Alzheimer’s disease, depression and schizophrenia. A postmortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex. J Neurol Sci 1981;51:465-72.
207 Moroji T, Watanabe N, Aoki N, Itoh S. Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia. Int Pharmacopsychiatry 1982;17:255-73.
208 Ferrier IN, Roberts GW, Crow TJ, Johnstone EC, Owens DG, Lee YC, et al. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci 1983;33:475-82.
209 Nair NP, Bloom DM, Debonnel G, Schwartz G, Mosticyan S. Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:711-4.
210 Gerner RH, van Kammen DP, Ninan PT. Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:73-82.
211 Ferrier IN, Crow TJ, Farmery SM, Roberts GW, Owen F, Adrian TE, et al. Reduced cholecystokinin levels in the limbic lobe in schizophrenia. A marker for pathology underlying the defect state? Ann NY Acad Sci 1985;448:495-506.
212 Lotstra F, Verbanck PM, Gilles C, Mendlewicz J, Vanderhaeghen JJ. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia. Ann NY Acad Sci 1985;448:507-17.
213 Farmery SM, Owen F, Poulter M, Crow TJ. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci 1985;36:473-7.
214 Fuxe K, Andersson K, Locatelli V, Agnati LF, Hökfelt T, Skirboll L, Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover indiscrete areas in the rat brain following intraventricular injection. Eur J Pharmacol 1980;67:329-31.
215 Agnati LF, Fuxe K, Benfenati F, Celani MF, Battistini N, Mutt V, et al. Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the rat. Neurosci Lett 1983;35:179-83.
216 Agnati LF, Fuxe K, Battistini N, Benfenati F. Aging brain and dopamine receptors: abnormal regulation by CCK-8 of 3H-spiperone labeled dopamine receptors in striatal membranes. Acta Physiol Scand 1984;120:465-7.
217 Penke B, Kovács GL, Zsigo J, Kadar T, Szabo G, Kovács K, et al. In vivo sulfation of cholecystokinin octapeptide. Possible interactions of the two forms of cholecystokinin with dopamine in the brain. Ann NY Acad Sci 1985;448:293-305.
218 Vasar EE, Otter MYa, Ryago LK. Intracerebroventricular administration of cholecystokinin inhibits the activity of the dopaminergic and serotoninergic systems of the brain. Neurosci Behav Physiol 1985;15:232-6.
219 Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann NY Acad Sci 1994;713:300-11.
220 Ravard S, Dourish CT. Cholecystokinin and anxiety. Trends Pharmacol Sci 1990;11:271-3.
221 Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 1991;88:1130-3.
222 Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci 1994;713:273-82.
223 Lydiard RB. Neuropeptides and anxiety: focus on cholecystokinin. Clin Chem 1994;40:315-8.
224 Hendrie CA, Neill JC, Shepherd JK, Dourish CT. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 1993;54:689-93.
225 Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993;14:244-9.
226 Tessari M, Maraia G, Reggiani A. Possible role of CCKB-receptors in anxiety: an "in vivo" study. Pharmacol Res 1992;25(Suppl. 1):55-6.
227 Harro J, Oreland L, Vasar E. Cholecystokinin receptors and animal models of anxiety. Clin Neuropharmacol 1992;15(Suppl. 1):A479-A480.
228 Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, et al. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 1997;154:700-2.
229 Cohen H, Kaplan Z, Kotler M. CCK-antagonists in a rat exposed to acute stress: implication for anxiety associated with post-traumatic stress disorder. Depress Anxiety 1999;10:8-17.
230 Koszycki D, Cox BJ, Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry 1993;150:1881-3 (comment in: Am J Psychiatry 1995;152:300-1).
231 Harro J, Kiivet RA, Lang A, Vasar E. Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 1990;39:63-71.
232 Pavlasevic S, Bednar I, Qureshi GA, Sodersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 1993;5:225-8.
233 Acosta GB. Administration of cholecystokinin sulphated octapeptide (CCK-8S) induces changes on rat amino acid tissue levels and on a behavioral test for anxiety. Gen Pharmacol 1998;31:637-41.
234 Deschodt-Lanckman M, Bui ND, Noyer M, Christophe J. Degradation of cholecystokinin-like peptides by a crude rat brain synaptosomal fraction: a study by high pressure liquid chromatography. Regul Pept 1981;2:15-30.
235 Rehfeld JF. Cholecystokinin and panic disorder – three unsettled questions. Regul Pept 2000;93:79-83.
236 Itoh S, Takashima A, Katsuura G. Effect of cholecystokinin tetrapeptide amide on the metabolism of 5-hydroxytryptamine in the rat brain. Neuropharmacology 1988;27:427-31.
237 van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 1996;6:187-94.
238 Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S, Karkanias C. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol Psychiatry 1992;32:903-12.
239 Bradwejn J, Koszycki D, Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 1990;35:83-5.
240 Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F, et al. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 2000;47:107-11.
241 Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, et al. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 1997;154:700-2.
242 Jerabek I, Boulenger JP, Bradwejn J, Lavallee YJ, Jolicoeur FB. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 1999;9:149-55.
243 Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 1998;8:1-7.
244 Bradwejn J, Koszycki D, Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatry Neurosci 1991;16:91-5.
245 Bradwejn J, Koszycki D. CCK receptors and panic symptoms in man. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple Cholecystokinin Receptors in the CNS. Oxford (UK): Oxford University Press, 1992:121-31.
246 van Megen HJ, den Boer JA, Westenberg HG. On the significance of cholecystokinin receptors in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1235-46.
247 McCann UD, Slate SO, Geraci M, Uhde TW. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1994-95;1:258-67.
248 Lines C, Challenor J, Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol 1995;39:235-42.
249 Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J, Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-93.
250 Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 1995;38:742-6.
251 van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl) 1997;129:243-8.
252 Le Melledo JM, Bradwejn J, Koszycki D, Bichet DG, Bellavance F. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry 1998;44:364-6.
253 Kellner M, Yassouridis A, Jahn H, Wiedemann K. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology (Berl) 1997;133:55-61.
254 Depot M, Merani S, Bradwejn J, Mukherjee J, Caille J, Gutkowska J, et al. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. J Psychiatry Neurosci 1998;23:298-304.
255 Depot M, Caille G, Mukherjee J, Katzman MA, Cadieux A, Bradwejn J. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 1999;20:177-87.
256 Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997;22:332-40.
257 van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl) 1997;129:357-64.
258 Ströhle A, Holsboer F, Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000;22:251-6.
259 Abelson JL, Le Melledo J, Bichet DG. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology 2001;24:161-9.
260 Jerabek I, Boulenger JP, Bradwejn J, Drumheller A, Lavallee YJ, Jolicoeur FB. CCK4-induced panic in healthy subjects II: neurochemical correlates. Eur Neuropsychopharmacol 1999;9:157-64.
261 Jerabek I, Boulenger JP, Bradwejn J, Lavallee YJ, Jolicoeur FB. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 1999;9:149-55.
262 Huston JP, Schildein S, Gerhardt P, Privou C, Fink H, Hasenohrl RU. Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s. Peptides 1998;19:27-37.
263 Rex A, Marsden CA, Fink H. Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study. Neurosci Lett 1997;228:79-82.
264 Jenck F, Martin JR, Moreau JL. Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 1996;6:291-8.
265 Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 1999;45:872-82.
266 Reiman EM. PET, panic disorder, and normal anticipatory anxiety. In: Ballenger JC, ed. Neurobiology of Panic Disorder. New York: Wiley-Liss 1990:245-70.
267 Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 1995;37:462-6.
268 Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 1999;46:860-2.
269 Sramek JJ, Kramer MS, Reines SA, Cutler NR. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Anxiety 1994-95;1:141-3.
270 Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995;15:428-34.
271 Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, et al. Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 1999;85:225-40.
272 Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 1993;58:123-31.
273 Graeff FG. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 1994;27:811-29.
274 Graeff FG, Viana MB, Mora PO. Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze. Pharmacol Biochem Behav 1996;53:171-7.
275 Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996;54:129-41.
276 Graeff FG, Netto CF, Zangrossi H Jr. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 1998;23:237-46.
277 Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. J Physiol 1979;286:401-15.
278 Leger L, Descarries L. Serotonin nerve terminals in the locus coeruleus of adult rat: a radioautographic study. Brain Res 1978;145:1-13.
279 Pickel VM, Joh TH, Reis DJ. A serotonergic innervation of noradrenergic neurons in nucleus locus coeruleus: demonstration by immunocytochemical localization of the transmitter specific enzymes tyrosine and tryptophan hydroxylase. Brain Res 1977;131:197-214.
280 Otellin VA, Gilerovich EG, Mikhailova NB. Target cells of serotoninergic innervation in the locus coeruleus. Neurosci Behav Physiol 1994;24:457-61.
281 Kaehler ST, Singewald N, Philippu A. Dependence of serotonin release in the locus coeruleus on dorsal raphe neuronal activity. Naunyn Schmiedebergs Arch Pharmacol 1999;359:386-93.
282 Iijima K, Sato M. An immunocytochemical study using the PAP method for tyrosine hydroxylase and serotonin in alternate sections, and in situ hybridization to detect tryptophan hydroxylase mRNA in the rat’s locus ceruleus. Acta Histochem 1991;90:159-72.
283 Lai YY, Barnes CD. A spinal projection of serotonergic neurons of the locus coeruleus in the cat. Neurosci Lett 1985;58:159-64.
284 Chiu TH, Yang YR, Yang JJ, Chen CL. Inhibition of locus coeruleus neurons by serotonin at high doses. Chin J Physiol 1995;38:153-7 (erratum in Chin J Physiol 1995;38:265).
285 Clement HW, Gemsa D, Wesemann W. Serotonin-norepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the Locus coeruleus of the rat. J Neural Transm Gen Sect 1992;88:11-23.
286 Ruiz-Ortega JA, Ugedo L, Pineda J, Garcia-Sevilla JA. The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin. Naunyn Schmiedebergs Arch Pharmacol 1995;352:121-6.
287 Aston-Jones G, Akaoka H, Charlety P, Chouvet G. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 1991;11:760-9.
288 Van Bockstaele EJ. Multiple substrates for serotonergic modulation of rat locus coeruleus neurons and relationships with kainate receptors. Brain Res Bull 2000;51:433-42.
289 Charlety PJ, Chergui K, Akaoka H, Saunier CF, Buda M, Aston-Jones G, et al. Serotonin differentially modulates responses mediated by specific excitatory amino acid receptors in the rat locus coeruleus. Eur J Neurosci 1993;5:1024-8.
290 Regenold JT, Illes P. Inhibitory adenosine A1-receptors on rat locus coeruleus neurones. An intracellular electrophysiological study. Naunyn Schmiedebergs Arch Pharmacol 1990;341:225-31.
291 Pan WJ, Osmanovic SS, Shefner SA. Characterization of the adenosine A1 receptor-activated potassium current in rat locus ceruleus neurons. J Pharmacol Exp Ther 1995;273:537-44.
292 Pan WJ, Osmanovic SS, Shefner SA. Adenosine decreases action potential duration by modulation of A-current in rat locus coeruleus neurons. J Neurosci 1994;14:1114-22.
293 Kaehler ST, Singewald N, Philippu A. Dependence of serotonin release in the locus coeruleus on dorsal raphe neuronal activity. Naunyn Schmiedebergs Arch Pharmacol 1999;359:386-93.
294 Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001;26:37-43.
295 Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22.
296 Aulakh CS, Mazzola-Pomietto P, Murphy DL. Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. Eur J Pharmacol 1995;282:65-70.
297 Todd KG, McManus DJ, Baker GB. Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Cell Mol Neurobiol 1995;15:361-70.
298 Harkin A, Nally R, Kelly JP, Leonard BE. Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and b1-adrenergic receptors in an animal model of depression. J Neural Transm 2000;107:1213-27.
299 McGrath C, Burrows GD, Norman TR. Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol 1998;356:121-6.
300 McGrath C, Norman TR. The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology (Berl) 1998;136:394-401.
301 Minneman KP, Dibner MD, Wolfe BB, Molinoff PB. b1- and b2-adrenergic receptors in rat cerebral cortex are independently regulated. Science 1979;204:866-8.
302 Sethy VH, Day JS, Cooper MM. Dose-dependent down-regulation of b-adrenergic receptors after chronic intravenous infusion of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:673-82.
303 Lahti RA, Sethy VH, Barsuhn C, Hester JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983;22:1277-82.
304 Sethy VH, Day JS, Cooper MM. Rapid changes in central beta-adrenergic receptors after chronic intravenous infusion of antidepressants. Res Commun Chem Pathol Pharmacol 1986;54:35-46.
305 Sethy VH, Hodges DH Jr. Alprazolam in a biochemical model of depression. Biochem Pharmacol 1982;31:3155-7.
306 Sethy VH, Hodges DH Jr. Role of b-adrenergic receptors in the antidepressant activity of alprazolam. Res Commun Chem Pathol Pharmacol 1982;36:329-32.
307 Gold MS, Pottash AL, Sweeney DR, Davies RK, Kleber HD. Clonidine decreases opiate withdrawal-related anxiety: possible opiate noradrenergic interaction in anxiety and panic. Subst Alcohol Actions Misuse 1980;1:239-46.
308 Roszell DK, Struger J. Single case study: panic disorder associated with opioid dependency and methadone maintenance treatment. Drug Alcohol Depend 1984;13:305-9.
309 Luby ED, Marrazzi MA. A panic attack precipitated by opiate blockade-a case study. J Clin Psychopharmacol 1987;7:361-2.
310 Eriksson E, Westberg P, Thuresson K, Modigh K, Ekman R, Widerlöv E. Increased cerebrospinal fluid levels of endorphin immunoreactivity in panic disorder. Neuropsychopharmacology 1989;2:225-8.
311 Moises HC. Electrophysiological correlates of presynaptic opiate receptor activation: reduction in norepinephrine-mediated inhibition from the locus coeruleus. Brain Res 1987;423:149-61.
312 Raymon HK, Leslie FM. Opioid effects on [3H]norepinephrine release from dissociated embryonic locus coeruleus cell cultures. J Neurochem 1994;62:1015-24.
313 Jorm CM, Stamford JA. Actions of morphine on noradrenaline efflux in the rat locus coeruleus are mediated via both opioid and a 2 adrenoceptor mechanisms. Br J Anaesth 1995;74:73-8.
314 Pinnock RD. Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitro. Brain Res 1992;583:237-46.
315 Jolas T, Nestler EJ, Aghajanian GK. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 2000;95:433-43.
316 Li YQ, Jia HG, Rao ZR, Shi JW. Serotonin-, substance P- or leucine-enkephalin-containing neurons in the midbrain periaqueductal gray and nucleus raphe dorsalis send projection fibers to the central amygdaloid nucleus in the rat. Neurosci Lett 1990;120:124-7.
317 Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999;60(Suppl. 22):12-7.
318 Guimarães FS, Russo AS, De Aguiar JC, Ballejo G, Graeff FG. Anxiogenic-like effect of CCK-8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple Cholecystokinin Receptors in the CNS. Oxford: Oxford University Press 1992:149-54.
319 Beitz AJ, Shepard RD, Wells WE. The periaqueductal gray-raphe magnus projection contains somatostatin, neurotensin and serotonin but not cholecystokinin. Brain Res 1983;261:132-7.
320 Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 1999;100:207-15.
321 Graeff FG; Guimarães FS; De Andrade TG; Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996;54:129-41.
322 Zgombick JM, Beck SG, Mahle CD, Craddock-Royal B, Maayani S. Pertussis toxin-sensitive guanine nucleotide-binding protein(S) couple adenosine A1 and 5-hydroxytryptamine1A receptors to the same effector systems in rat hippocampus: biochemical and electrophysiological studies. Mol Pharmacol 1989;35:484-94.
323 Kochman RL, Grey TR, Hirsch JD. Cholecystokinin in vivo reduces binding to rat hypothalamic b-adrenergic sites. Peptides 1984;5:499-502.
324 Raiteri M, Paudice P, Vallebuona F. Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 1993;347:111-4.
325 Higuchi H, Kamata M, Yoshimoto M, Shimisu T, Hishikawa Y. Panic attacks in patients with chronic schizophrenia: a complication of long-term neuroleptic treatment. Psychiatry Clin Neurosci 1999;53:91-4.
326 Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E. Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry 2001;58:114-9.
327 Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998;155:603-9.
328 Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-9.